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ABSTRACT The MASH genes are vertebrate homologues
of achaete-scute, genes required for neuronal determination in
Drosophila. The sequence of MASH1 and MASH2 contains a
basic helix-oop-helix (bHLH) motif that is present in other
transcriptional regulators such as MyoD and E12. In the
absence of an authentic target for the MASH proteins, we
examined their DNA binding and transcriptional regulatory
activity by using a binding site (the E box) from the muscle
creatine kinase (MCK) gene, a target ofMyoD. Like myogenic
bHLH proteins, theMASH proteins form heterooligomers with
E12 that bind the MCK E box with high affinity in vitro.
Unexpectedly, however, MASH1 and MASH2 also activate
transcription of both exogenous and endogenous MCK in
transfected C3H/1OTI/2 fibroblasts. However, they do not
induce myogenesis. Myogenic activity is not exclusively a
property of the MyoD basic region, as substitution of this
domain fails to confer myogenic activity on MASH1. These data
suggest that different bHLH proteins may activate overlapping
but distinct sets of target genes in the same cell type.
The MASH genes are mammalian homologues of the neu-
ronal determination genes of the Drosophila achaete-scute
complex (1). Like its Drosophila counterparts, MASH) is
specifically expressed in the developing nervous system (2).
The MASH gene products are members of the basic helix-
loop-helix (bHLH) family of transcription factors, whose
members include the myc gene products (3) and MyoD (for
review see ref. 4) and which appear to be involved in the
control of proliferation and cell type determination. Members
ofthebHLH family share acommon basic region required for
DNA binding and a helix-loop-helix domain required for
homo- and heterodimer formation (5, 6).
Heterodimers between E12/E47 and MyoD (or other myo-
genic bHLH proteins) bind a core consensus site, CANNTG,
termed the E box (6-9). The E box is present in the IgH
enhancer-like element of the muscle-specific creatine kinase
(MCK) enhancer (10), as well as in the E2 element ofthe IgK
enhancer (5), which appear to be downstream targets of
E12/E47 and myogenic bHLH proteins, respectively. Het-
erodimers of E12 and the Drosophila achaete-scute protein
T3 will bind the E-box sequences in the IgK enhancer in vitro
(7).
We wished to determine whether, as predicted by their
amino acid sequences, the MASH genes encode DNA-
binding and transcriptional regulatory proteins. In the ab-
sence of an authentic target for the MASH proteins, we used
the MCK E box, which has been shown to bind heterodimers
of Drosophila scute (T4) and E12 in vitro (6). We found that
both MASH1 and MASH2 form high-affinity E-box-binding
complexes as heterooligomers with E12, confirming that they
are DNA-binding proteins. Since DNA binding is a necessary
but not sufficient condition for transcriptional regulation (6,
11), we also tested the ability of the MASH genes to activate
transcription of the MCK enhancer. Unlike Drosophila scute
and E12, which bind the MCK E box but do not activate
transcription from this site (6, 11), the MASH genes activate
transcription of both exogenous and endogenous MCK in
C3H/10T'/2 cells. However, in contrast to MyoD, these genes
do not activate the full myogenic program. Substitution ofthe
MyoD basic region in MASH1 fails to convert MASH1 to a
myogenic protein.
MATERIALS AND METHODS
In vitro transcription, translation, immunoprecipitation, and
electrophoretic mobility shift assay (EMSA) assays were
performed by using a reticulocyte lysate system as described
(6, 12). Wild-type and mutant E-box oligonucleotides from
the IgH enhancer-like sequence in the MCK enhancer (right
E box) are as follows: wild-type top strand, GATC-
CCCCCAACACCTGCTGCCTGA; mutant top strand,
GATCCCCCCAACACGGTAACCCTGA (10, 13).
C3H/10T1/2 mouse embryo fibroblasts were maintained
and transfected essentially as described (12). P-Galactosidase
staining was performed as described (14). Endogenous my-
osin and MCK expression were detected by using MF20
hybridoma supernatant (15) and MCK polyclonal antibody
(16), respectively, and a Vectastain ABC kit. Cultures were
harvested and assayed for chloramphenicol acetyltransferase
(CAT) activity as described (17).
Plasmids that have been described previously are RSVL
(18), 3300MCKCAT (13), and SVC11S (19). Plasmid pMaori3
is a cytomegalovirus-promoted lacZ gene that includes a
nuclear localization signal (M. Weber, personal communica-
tion). (2E)80MCKCAT (J. Buskin, personal communication)
contains two wild-type E-box oligonucleotides (same as those
used in the EMSA) oriented 5'/3':3'/5' upstream of80MCK-
CAT (13). (2mE)80MCKCAT (J. Buskin, personal communi-
cation) contains two mutant E-box oligonucleotides (same as
those used in the EMSA) oriented 3'/5':3'/5' also upstream of
80MCKCAT. pRSVMASH1 is pRSVSV40 (20) containing a
1.4-kilobase (kb) MASH) cDNA (1), pRSVMASH1E contains
a truncated MASH) cDNA (20), pRSVMASH2 contains a
1.4-kb MASH2 cDNA, pRSVMyoD contains the 1.8-kb MyoD
cDNA (21). Oligonucleotide site-directed mutagenesis (Am-
ersham kit) of MASH) and MyoD was used to generate the
basic region deletion and substitution constructs (see Table 1).
RESULTS
MASH1 andMASH2 Are DNA-Binding Proteins. Neither the
MASH1 norMASH2 in vitro translation products were able to
Abbreviations: MCK, muscle creatine kinase; bHLH, basic helix-
loop-helix; EMSA, electrophoretic mobility shift assay(s); CAT,
chloramphenicol acetyltransferase; RSV, Rous sarcoma virus.
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bind an oligonucleotide containing an MCK E box (see Ma-
terials and Methods), when assayed by an EMSA (data not
shown). A similar result was obtained for in vitro-translated
MyoD assayed in parallel (data not shown), consistent with
previous observations (6). The affinity ofMyoD for the E box
is strongly increased by interaction with E12/E47 (5, 7) (Fig.
1, lane 1). Similarly, both MASH1 and MASH2 in combination
with a rat E12 protein (S.J.B., unpublished data) formed
E-box-binding complexes of similar size (Fig. 1, lanes 6 and
11). Binding was abolished by competition with excess wild-
type oligonucleotide (Fig. 1, lanes 2 and 3, 7 and 8, and 12 and
13), but not by a mutant oligonucleotide unable to compete for
MyoD/E12 binding to the E box (Fig. 1, lanes 4 and 5, 9 and
10, and 14 and 15). These data indicate that MASH1 and
MASH2 like MyoD form high-affinity E-box-binding heteroo-
ligomeric complexes with E12. However, MyoD plus E12 ran
as a doublet, suggestive of higher order oligomers, whereas
MASH1 plus E12 formed a single band under our conditions.
Studies using bacterially expressed MASH1 indicate that
homooligomers will bind the MCK E box, but only at micro-
molar concentrations (data not shown).
To determine whether the interaction between MASH1
and E12 is dependent on the presence ofDNA, we performed
coimmunoprecipitation experiments with a specific anti-
MASH1 monoclonal antibody (2). As shown in Fig. 2, when
the E12R (5) and MASH1 proteins were mixed prior to
immunoprecipitation, E12R was recovered in the immuno-
precipitate (Fig. 2, lane 2), indicating an interaction with
MASHL. The amount of E12R coprecipitated by anti-
MASH1 was not changed by the presence of unlabeled
wild-type or mutant E-box-containing oligonucleotide (Fig.
2, lanes 3 and 4). These data indicate a direct interaction
between MASH1 and E12 that is not quantitatively influ-
enced by the presence of their DNA-binding site. The effi-
ciency of heterooligomerization appears low and may reflect
an instability of the complexes under our conditions of
immunoprecipitation and washing. We have been unable to
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FIG. 1. DNA binding of MASH-E12 complexes with the MCK
enhancer. EMSA were performed by using in vitro-translated pro-
teins mixed with a 32P-labeled oligonucleotide from the MCK en-
hancer in a final volume of 20 ,ul. Lanes 1-5, MyoD and rat E12
combined; lanes 6-10, MASH1 and rat E12 combined; lanes 11-15,
MASH2 and rat E12 combined. The numbers in the lanes refer to the
fold excess of unlabeled wild-type (wt) or mutant (mt) oligonucleo-
tide added to the assay. The lower shifted band that appears with the
excess wild-type oligonucleotide (lanes 2, 3, 7, 8, 12, and 13) was also
seen in control reticulocyte lysates (data not shown) and may
represent low-affinity binding of a bHLH protein present in the
lysate; such a protein has been implicated by the studies of Blackwell
and Weintraub (22). The region of the gel with the unbound oligo-
nucleotide probe is not shown. Analysis of [35S]methionine-labeled,
in vitro-translated MyoD, E12, MASH1, and MASH2 by SDS/
PAGE indicated that similar amounts of these proteins were syn-
thesized and added to the gel shift reactions (data not shown).
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FIG. 2. Coimmunoprecipitation of MASHi and E12. In vitro-
translated [35S]methionine-labeled MASHi and E12 proteins were
coimmunoprecipitated by a monoclonal antibody recognizing
MASH (2). Lane 1, total reticulocyte lysate products; lanes 2-4,
immunoprecipitation of E12R (7) plus MASHi; lane 5, MASHi
alone; lane 6, E12R alone. Wild-type (wt) or mutant (mt) MCK
oligonucleotide was added to lane 3 or 4, respectively.
examine interactions between MASH1 and E12 in vivo, due
to an inability to immunoprecipitate MASH1 from whole cell
lysates with our monoclonal antibody (T.S., unpublished
results).
MASH and MASH2 Activate Transcription from the MCK
Enhancer. Previous studies of bHLH proteins have demon-
strated that DNA binding is necessary but not sufficient for
transcriptional activation (6, 11). We therefore asked whether
MASH1 and MASH2 were able to influence transcription of
a CAT reporter gene under the control of the MCK enhancer.
This promoter, comprising 3300 base pairs (bp) of MCK 5'
flanking DNA, is normally inactive in 10T½/2 cells but is
strongly activated by cotransfection of MyoD expression
constructs (6, 10). Both MASH1 and MASH2 activated
transcription from the 3300MCKCAT reporter gene in tran-
siently transfected 10T1/2 cells (Fig. 3A, lanes 4-6). By
contrast, E12 did not transactivate this gene (Fig. 3A, lane 2).
The activity of MASH1 was not significantly affected by
deletion of a 558-bp fragment containing the 5' untranslated
region and the first six amino acids (Fig. 3A, compare
MASH1 and MASH1-E). The extent of transactivation by
MASH1 and MASH2 (80- and 160-fold relative to the RSVL
control, respectively) appears 20- to 40-fold lower than that
obtained with MyoD in parallel (Fig. 3A, lane 3 and data not
shown). However, in this experiment, expression of the
MASH genes and MyoD was driven by different promoters.
In subsequent experiments, when both MyoD and MASH]
were under the control of the RSV enhancer, transactivation
of 3300MCKCAT by MASH1 was 60% of that obtained with
MyoD (Fig. 4A, lanes 1 and 4; Table 1). Transactivation by
MyoD and the MASH genes did not require exogenous E12,
suggesting that 1OT'/2 cells contain endogenous E12-like
activity, consistent with previous data (12).
To determine whether E-box elements in the MCK en-
hancer were responsible for transactivation ofMCKCAT by
MASH1 and MASH2, we used a reporter construct with two
adjacent E-box-containing oligonucleotides placed upstream
of a minimal 80-bp MCK promoter [(2E)80MCKCAT]. This
E box-reporter construct was transactivated by MASH1 and
MASH2 to an extent similar to 3300MCKCAT (Fig. 3B, lanes
4-6; Fig. 4B, lanes 1 and 4; Table 1). In contrast, transfection
of the rat E12 expression vector did not activate the minimal
E-box dimer-reporter construct (Fig. 3B, lane 2). Transac-
tivation of these minimal constructs is dependent upon the
E-box sequence, since a mutation in this site that eliminates
MASH1 or MASH2 DNA binding in vitro (Fig. 1, lanes 9, 10,
14, and 15) greatly reduces (by 20-fold) transactivation by
these proteins in vivo (Fig. 3C, lanes 4-6). Taken together,
these results indicate that MASH1 and MASH2 not only bind
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FIG. 3. Transactivation of MCKCAT reporter genes by the
MASH genes and MyoD. CAT activity was assayed in extracts from
10T1/2 cells transiently cotransfected with 5 ,ug of the reporter gene
3300MCKCAT (A), (2E)80MCKCAT (B), or (2mE)80MCKCAT (C)
and 10 ,ug of an expression construct containing either luciferase
(RSVL) (lanes 1), rat E12 (lanes 2), MyoD (SVC11s) (lanes 3),
MASH2 (lanes 4), MASH1 (lanes 5), or a truncated MASH1 lacking
the 5' nontranslated region and the first six amino acids (MASH1-E)
(lanes 6). 3300MCKCAT contains 3300 bp of MCK 5' sequence.
(2E)80MCKCAT contains two E-box oligonucleotides from the
MCK enhancer fused to 80 bp of MCK basal promoter. (2mE)-
80MCKCAT is similar to (2E)80MCKCAT except that mutant E-box
oligonucleotides are present. Note that all expression constructs
used the Rous sarcoma virus (RSV) long terminal repeat except
MyoD, which was expressed from the simian virus 40 early pro-
moter. Equal amounts of protein were added to each reaction
mixture.
theMCK E box but also act to enhance transcription ofa gene
that contains these sites. As in the case of MyoD, transac-
tivation of MCK by the MASH genes was abolished by
cotransfection of Id (data not shown), a mammalian homo-
logue ofDrosophila extramacrochaete (12). Thus, the genetic
and biochemical interactions between achaete-scute, daugh-
terless, and extramacrochaete in Drosophila (23) may be
reflected in functional interactions between their mammalian
homologues MASH, E12, and Id, respectively. Whether such
interactions are important in vivo remains to be determined.
MASH1 Activates Endogenous MCK Expression, but Not
the Entire Myogenic Program, in 10T1/2 Cells. The foregoing
results raised the question of whether the MASH genes, like
MyoD (21), could induce expression of the endogenous
myogenic differentiation program in fibroblasts. Transient
transfection of MASH] into 1OT'/2 cells failed to induce
muscle differentiation as indicated by the lack of cell fusion
.~~~~~~~~~~~~~~~~~~~~~~~~~~
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FIG. 4. Activity of basic region exchange mutants ofMASH1 and
MyoD. CAT assays were performed on extracts of 10T1/2 cells
transiently cotransfected with 5 ,ug of the reporter gene 3300MCK-
CAT (A) or (2E)80MCKCAT (B) and 10 jg of an RSV expression
vector containing either MASH1 (lanes 1), MASH1 with the MyoD
basic region (MASHmyo-b; lanes 2), MASH1 with the basic region
deleted (MASH&b; lanes 3), MyoD (lanes 4), or MyoD with the
MASH1 basic region (MYODmash-b; lanes 5). Equal amounts of
protein were added to each lane.
or expression of myosin heavy chain, a muscle-specific
marker (15) (Fig. SC). By contrast, abundant expression of
myosin was detected after MyoD transfection (Fig. SF).
Nevertheless, transfection of MASH) activated expression
of the endogenous MCK gene in at least 10% of the trans-
fected cells, as determined by staining with a specific anti-
MCK antibody (16) (Fig. 5 A and B; Table 1). Thus, MASH1
activates transcription of both exogenous and endogenous
MCK. However, this activity is not accompanied by full
myogenic conversion of the 1OTY2 cells.
Detailed mutagenic studies have suggested that the MyoD
basic region is not only necessary for DNA binding but also
contains a "recognition code" necessary for myogenic ac-
tivity (6). As expected, deletion of the MASH1 basic region
abolished its ability to transactivate the exogenous and
endogenous MCK enhancer (Fig. 4 A and B, lanes 3; Table
1). Substitution of the MASH1 basic region into MyoD
reduced the ability of MyoD to activate exogenous (Fig. 4 A
and B, lanes 5) and endogenous (Fig. SH) MCK transcription,
but clearly preserved some activity (Table 1). However, this
replacement mutation abolished myogenic activity (Fig. SI),
indicating that MyoD containing a MASH1 basic region
behaves similarly to intact MASHi. To determine whether
the MyoD basic region was sufficient to convert MASH1 to
a myogenic protein, we substituted the MyoD basic region for
that ofMASH1 (Table 1). Although such chimeric constructs
activated transcription of both exogenous (Fig. 4 A and B,
lanes 2) and endogenous (Fig. 5K) MCK genes, they failed to
induce complete myogenesis as assayed by myosin expres-
sion (Fig. 5L) or cell fusion, again behaving qualitatively like
intact MASHi. These data support the idea that the MyoD
basic region is necessary for myogenesis, but they reveal that
A
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Table 1. Sequence and activity of MASH1 and MyoD basic region exchange mutants
CAT activityt % f3-gal' cellst
Construct Amino acid sequence* 3300MCKCAT (2E)80MCKCAT MCK' Myosin'
basic region
4MASH1 ... FSGFGYSLPQQQPIIVARRNERERNRVKLVNL... 60 24 11 0
MASHlAb ....FSGFGY VKLVNL ... 0.5 0.2 0 0
MASH1myo-b ..FSGFGYKRKTTNADRRK&ATERERRRVKLVNL ... 34 5.0 25 0
MyoD .. WACKACKRKTTNADRRKLATERERRRLSKVNE .. 100 100 >100 >100
MYODmash-b ... .WACKACSLPQQQP&AVERRNERERNRLSKVNE... 11 1.8 3 0
RSVL (control) 0.7 0.2 0 0
*The amino acids exchanged in the expression constructs used for the experiments illustrated in Figs. 4 and 5 are shown in boldfaced type. The
line over the sequence shows the basic region conserved between members of the bHLH family.
tCAT activity is shown relative to that of MyoD, which was set to 100. The data are the average of two independent experiments, one of which
is shown in Fig. 4.
1The percentage oftransfected (B-gal') cells expressing MCK or myosin immunoreactivity is shown. The data are the average oftwo independent
experiments, one of which is shown in Fig. 5.
this domain is insufficient to confer full myogenic activity
upon a heterologous tissue-specific bHLH protein.
DISCUSSION
MASH) and MASH2 Encode Transcriptional Regulatory
Proteins. We have analyzed the DNA-binding and transcrip-
tional regulatory properties of MASH1 and MASH2, two
mammalian homologues of achaete-scute, by using the MCK
E box as a model target site. In vitro, both MASH1 and
MASH2 bind the MCK E box with high affinity when
MASH MYOD
9
complexed with E12. In vivo, both MASH genes cause a
transcriptional activation of reporter constructs containing
the MCK E box. This activation is dependent upon the E-box
sequence, since mutations in that site that abolish binding of
the MASH proteins in vitro abolish transactivation in vivo. It
is possible that the action of the transfected MASH genes on
MCK is indirect and mediated by induction of endogenous
myogenic regulators. We consider this possibility unlikely,
however, as myogenic bHLH proteins activate not only
MCK but also myosin expression and myoblast fusion in
MYOD
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FIG. 5. Induction of endogenous MCK expression but not myogenesis in 10T'/2 cells expressing MASH1. 10T1/2 cells were transiently
cotransfected with 5 ,ug of pMaori3 (cytomegalovirus-promoted nuclear-localized lacZ) and 20 ,ug of an RSV expression vector containing either
MASH1-E (A-C), MyoD (D-F), MyoD with the MASH1 basic region (MYODmash-b) (G-I), or MASH1 with the MyoD basic region
(MASHlmyo-b) (J-L) (see Table 1 for the sequences of the exchange mutants). Parallel wells were assayed for expression of ,-galactosidase
(a-gal) (A, D, G, and J), MCK (B, E, H, and K), or myosin (C, F, I, and L) (see Materials and Methods). The percentage of MCK-positive
and myosin-positive cells present in each condition is given in Table 1.
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10T'/2 cells (4, 21, 24)-responses not observed upon MASH
transfection. Indeed, we observe that endogenous MyoD and
myogenin mRNAs are not induced by transfection ofMASH
genes (J.E.J., unpublished data). Therefore, the MCK en-
hancer behaves as a transcriptional activation target of the
MASH genes, although based upon its expression pattern (2),
MCK is unlikely to be an authentic target ofMASH1 in vivo.
MCK Expression Can Be Uncoupled from the Full Myogenic
Program. If most or all bHLH proteins can bind the MCK E
box in vitro, why do they not all activate myogenesis in vivo?
Previous studies have explained this paradox by the fact that
proteins such as E12 or T4 bind the MCK E box but do not
activate transcription. Such an explanation cannot account
for the lack of myogenic activity by the MASH genes,
however, because they activate transcription of both exog-
enous and endogenous MCK. Given that the MASH and
scute (T4) proteins differ in the basic region by only 2 out of
11 amino acids (1), it is curious that these regions had
different effects when substituted for the basic region of
MyoD. While we cannot rule out differences in transfection
or assay conditions as the source of this apparent inconsis-
tency, it may be explained by the fact that not only the basic
region but also the adjacent N-terminal 9 amino acids have
been replaced in both substitution mutations (Table 1 and ref.
6). MASH1 and scute differ at 8 out of 9 positions in this
adjacent region. This lack of conservation may explain the
difference in the ability of these two genes to activate
transcription of the MCK enhancer.
If the MASH genes are able to activate MCK expression,
why do they not activate the full myogenic program? One
possibility is that the in vivo activation of muscle-specific E
boxes by MASH proteins is weaker than by myogenic bHLH
proteins. Consistent with this idea, MASH activated endog-
enous MCK in only 10o of transfected 10TY2 cells, whereas
MyoD activated MCK in 100lo ofthese cells. Another possible
explanation is that the MASH proteins cannot activate addi-
tional endogenous myogenic bHLH genes, as well as non-
bHLH myogenic regulatory factors (25, 26), which are acti-
vated by transfection of MyoD (24, 27). Consistent with this
idea, myogenin mRNA was detected in MyoD-transfected
10T1/2 cells, but not in MASH-transfected cells (J.E.J., un-
published data). These results suggest that the myogenic
activity oftransfected MyoD may be due primarily to its ability
to activate transcription of endogenous myogenic regulators,
which in turn activate terminal differentiation genes such as
MCK. In any case, the uncoupling of MCK expression from
the full myogenic program provides an indication that the
coordinate activation ofdifferent muscle-specific genes during
myogenesis can be molecularly dissected.
The fact that MyoD and MASH both activate MCK but
only MyoD activates myogenesis implies that these bHLH
proteins are able to regulate overlapping but distinct subsets
of target genes in 10T1/2 cells. Can this be explained by
differences in the basic regions of the two proteins? Although
substitution of the MyoD basic region into MASH1 produced
a slight enhancement of MCK transactivation, it did not
convert MASH1 to a myogenic protein (Fig. 5L). A similar
result was obtained when the myogenin basic region was
substituted into E12 (28). These results imply that the portion
of the MyoD basic region substituted in these experiments is
not sufficient to confer myogenic activity on a heterologous
bHLH protein. Such a conclusion may seem contrary to the
observation that the MyoD bHLH domain alone induces
myogenesis when stably transfected into 10T'/2 cells (29).
However, recent data suggest that the inclusion of amino
acids adjacent (C-terminal) to the MyoD basic region confers
myogenic activity on an E12-MyoD basic chimeric protein
(H. Weintraub, personal communication). Thus, residues of
MyoD flanking the basic region are also needed for its
myogenic activity. Myogenic activity may also depend on
other functional domains of MyoD, as suggested by detailed
studies of a MyoD-E12 basic chimeric protein (11).
The studies presented in this paper confirm that the MASH
genes encode transcriptional regulatory proteins, as pre-
dicted by their deduced amino acid sequences. This activity
was revealed by using a model enhancer from a gene that is
unlikely to be an authentic target ofMASH regulation in vivo.
However, it provides the opportunity to examine the func-
tional interactions between MASH and other genes, as well
as to dissect functional domains within the MASH proteins.
This information should be helpful in designing experiments
aimed at interfering with MASH function in vivo, as well as
in achieving a clearer understanding of how the functional
specificity ofbHLH proteins is determined by their structure.
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